Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging
| Autor: | Estella P.S. Tong, Henrik Zetterberg, John Hardy, Amy K.Y. Fu, Fanny C.F. Ip, Ronnie M. N. Lo, Vincent Mok, Kin Y. Mok, Andrew Lung-Tat Chan, Xiaopu Zhou, Bonnie W.Y. Wong, Kit Cheung, Yu Chen, Timothy Kwok, Nancy Y. Ip, Yuanbing Jiang, Nicole C. H. Lai, Philip C.H. Chan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Proteomics
0301 basic medicine Amyloid Endophenotypes Epidemiology tau Proteins Disease Computational biology Cohort Studies 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Developmental Neuroscience Disease Screening Alzheimer Disease medicine Humans Mass Screening Phosphorylation Aged Amyloid beta-Peptides business.industry Proteomic Profiling Health Policy Neurodegeneration Area under the curve Reproducibility of Results Middle Aged medicine.disease Blood proteins 3. Good health Psychiatry and Mental health 030104 developmental biology Proteome Hong Kong Neurology (clinical) Geriatrics and Gerontology business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Alzheimer's & Dementia. 18:88-102 |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1002/alz.12369 |
| Popis: | Introduction Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD. Methods We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high-throughput proximity extension assay and validated the results in an independent cohort. In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD. Results We identified 429 proteins that were dysregulated in AD plasma. We selected 19 "hub proteins" representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690-0.9816) and associated endophenotypes. Moreover, specific hub proteins exhibit disease stage-dependent dysregulation, which can delineate AD stages. Discussion This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high-performance, blood-based test for clinical AD screening and staging. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|